Direct comparison of these two cohorts shows a significant difference of ADAM17 levels between the patient cohort vs. control cohort (U-test, p < 0.001); ADAM17 values are significantly higher in the patient group than in the control group (average: patients diagnosed ovarian cancer: 3753 pg/mL, control: 2197 pg/mL). The gene discussed is ADAM17; the disease is ovarian carcinoma.